Evidence map›Paper›PMID 42737505›Full record

ArticleInternational journal of molecular sciences2026

Thiazole-Substituted Benzoylpiperazines with Anti-Cancer and Anti-Inflammatory Activities: Comparative Evaluation with Lercanidipine.

Sevde Nur Biltekin Kaleli

Abstract readComparative Study
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Sevde Nur Biltekin KaleliDepartment of Pharmaceutical Microbiology, School of Pharmacy, Istanbul Medipol University, 34810 Istanbul, Türkiye.ORCID 0000-0003-1896-2729

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lercanidipine has previously been investigated in our laboratory as a reference compound in cancer-related combination studies, providing a comparative framework for the present evaluation of thiazole-substituted benzoylpiperazines. In the present study, we evaluated the cytotoxic, anti-inflammatory, and p38α MAPK-related activities of thiazole-substituted benzoylpiperazine derivatives. The cytotoxic profiles of the derivatives were evaluated in multiple human cancer cell lines using the MTT assay. Compound

Indexed as

Anti-Inflammatory AgentsAntineoplastic AgentsDihydropyridinesPiperazinesThiazolesAnimalsApoptosisCell Line, TumorHumansMolecular Docking Simulationp38 Mitogen-Activated Protein KinasesStructure-Activity RelationshipTumor Necrosis Factor-alphaAnti-Inflammatory AgentsAntineoplastic AgentsDihydropyridineslercanidipinep38 Mitogen-Activated Protein KinasesPiperazinesThiazolesTumor Necrosis Factor-alphaanti-inflammatoryapoptosiscisplatinlercanidipinethiazole-substituted benzoylpiperazines

Identifiers

PMID42737505
PMCPMC13566115

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.